



PRAXIS
PEPTIDE INSTITUTE

HCG

ADVANCED MECHANISM AND EVIDENCE GUIDE

LONG-ACTING LH-RECEPTOR SIGNAL FOR PREGNANCY AND GONADAL FUNCTION

glycoprotein • trophoblast • LHCGR • corpus luteum • progesterone • ovulation • testosterone • fertility

MEMORY KEY: HCG IS A LONG-ACTING LH-RECEPTOR SIGNAL: THE TARGET TISSUE AND CLINICAL GOAL DETERMINE ITS MEANING.

Educational monograph • Foundational pregnancy physiology • Established fertility and selected central-hypogonadism applications

HOW TO USE THIS GUIDE

This guide converts a long-form research narrative into a repeatable learning system. Every future PPI molecule guide can use the same architecture, visual language, evidence labels, and memory devices.

01	IDENTITY What it is - and what it is not
02	PHYSIOLOGY The normal system before the compound
03	MECHANISM Target, pathway, and downstream logic
04	EVIDENCE Cell, animal, and human evidence separated
05	RISK Known concerns, unknowns, and translation limits
06	MONITORING What a legitimate research framework would measure
07	PATIENT CONTEXT Which phenotype might fit the biology
08	RECALL Memory hooks, seven questions, and bottom line

EVIDENCE CODE	CELL = mechanistic ANIMAL = organism-level preclinical HUMAN = clinical translation	CORE DISCIPLINE Mechanism does not equal outcome. Unknown does not equal failed - and unknown does not equal proven.
------------------	---	---

RAPID RECALL

Read this page first. These anchors provide the complete high-level story of Hcg; the remaining pages add mechanism, evidence, context, and nuance.

01	IDENTITY A trophoblast-derived glycoprotein hormone with alpha and beta subunits; pregnancy testing primarily detects beta-hCG.
02	RECEPTOR Activates LHCGR through Gs, cAMP, PKA, and broader signaling in ovarian and Leydig cells.
03	PREGNANCY Rescues the corpus luteum after implantation so progesterone persists until placental steroidogenesis takes over.
04	WOMEN Can trigger final oocyte maturation and ovulation after adequate follicular development.
05	MEN Bypasses the pituitary and directly stimulates Leydig-cell LHCGR to support intratesticular testosterone.
06	LIMIT hCG provides LH-like signaling, not FSH; testosterone production does not guarantee spermatogenesis or fertility.
07	TRADEOFF Its prolonged receptor activity is useful clinically but can increase OHSS risk in susceptible stimulated ovaries.
08	PRAXIS QUESTION Which LHCGR-dependent function is targeted, can the gonad respond, and did the intended outcome occur?

ONE-SENTENCE MEMORY
HCG IS A LONG-ACTING LH-RECEPTOR SIGNAL: THE TARGET TISSUE AND CLINICAL GOAL DETERMINE ITS MEANING.

UNDERSTAND THE PEPTIDE

hCG - human chorionic gonadotropin - is a glycoprotein hormone produced predominantly by trophoblast tissue after implantation and is one of the most important endocrine signals of early pregnancy.

Its most famous role is:

MAINTAIN THE CORPUS LUTEUM.

But hCG has a broader biological identity.

It acts through the same major receptor used by:

LH - LUTEINIZING HORMONE.

That receptor is:

LHCGR - LUTEINIZING HORMONE / CHORIONIC GONADOTROPIN RECEPTOR.

So hCG can mimic important aspects of LH signaling in:

- ovarian theca cells
- Leydig cells
- luteal cells
- selected reproductive tissues

This gives hCG relevance to:

- early pregnancy
- ovulation
- male testosterone production
- hypogonadotropic hypogonadism
- progesterone maintenance
- final oocyte maturation
- male fertility

IVF

- cryptorchidism research and historical therapy
- reproductive diagnostic testing

The best way to understand hCG is not:

“THE PREGNANCY HORMONE.”

That is too narrow.

A better description is:

A LONG-ACTING LH-RECEPTOR SIGNAL THAT PRESERVES EARLY PREGNANCY BY MAINTAINING LUTEAL STEROIDOGENESIS AND can also be used pharmacologically to activate gonadal LH-receptor biology in both women and men.

That is the core biology.

WHAT IS hCG?

hCG is a:

GLYCOPROTEIN HORMONE.

It is composed of two subunits:

ALPHA SUBUNIT

and:

BETA SUBUNIT.

The alpha subunit is structurally related to the alpha subunits of:

LH

FSH

TSH

The beta subunit provides much of:

THE HORMONE'S BIOLOGICAL SPECIFICITY.

This is why pregnancy tests primarily detect:

β -hCG.

hCG is produced predominantly by:

SYNCYTIOTROPHOBLAST

after implantation.


Its concentrations rise rapidly during:

EARLY PREGNANCY.

This gives us the first major concept:

THE EMBRYO / PLACENTA BEGINS SIGNALING THE MATERNAL ENDOCRINE SYSTEM VERY EARLY.

THE IDENTITY MODEL



- Early pregnancy maintained

The core concept is:

hCG TELLS THE OVARY THAT PREGNANCY HAS OCCURRED AND THAT THE CORPUS LUTEUM SHOULD NOT SHUT DOWN.

WHY THE CORPUS LUTEUM MATTERS

After ovulation:

the ruptured follicle becomes the:

CORPUS LUTEUM.

Its major early function is:

PROGESTERONE PRODUCTION.

Progesterone helps maintain:

- endometrial stability
- uterine receptivity
- early pregnancy support

But without pregnancy:

the corpus luteum naturally
regresses.



Progesterone falls.



Menstruation occurs.

Pregnancy therefore needs a way to tell the ovary:

DO NOT LET THE CORPUS LUTEUM DIE YET.

That signal is:

hCG.

THE CORPUS-LUTEUM RESCUE MODEL

Ovulation



Corpus luteum forms



Progesterone ↑

If no pregnancy:



LH support falls



Corpus luteum
regresses



Progesterone ↓



Menstruation

But if
implantation
occurs:



Trophoblast
releases hCG



LHCGR
activation



Corpus luteum
rescued



Progesterone
maintained



EARLY
PREGNANCY
SUPPORTED

This is one of the cleanest endocrine rescue systems in human physiology.

hCG VS LH

This comparison is fundamental.

Both hCG and LH activate:

LHCGR.

But they are not identical signals.

LH

Produced by:

ANTERIOR PITUITARY.

Primary roles:

- ovulation
- ovarian androgen production
- luteinization
- testicular testosterone production

hCG

Produced primarily by:

PLACENTAL TROPHOBLAST.

Primary physiological role:

PROLONGED LHCGR STIMULATION DURING EARLY PREGNANCY.

One of the major pharmacological differences is:

HALF-LIFE.

hCG persists much longer than LH.

That means:

SAME RECEPTOR DOES NOT MEAN SAME SIGNAL DURATION.

This is enormously important in fertility medicine.

THE SIGNAL-DURATION MODEL

LH



shorter physiological signal

versus:

hCG

- more prolonged receptor activation

Both:



LHCGR

But:

DURATION + SIGNALING INTENSITY DIFFER.

Again:

RECEPTOR IDENTITY $\neq$ PHARMACOLOGICAL IDENTITY.

THE LHCGR RECEPTOR

hCG acts through:

LHCGR.

This is a:

G-PROTEIN-COUPLED RECEPTOR.

Its major classical signaling pathway is:

Gs → **adenylyl cyclase** → **cAMP ↑** → **PKA** → **steroidogenic signaling**

But LHCGR biology is more complex than one pathway.

Current receptor research also describes signaling through:

- Gq/11
- β -arrestin
- Gi
- MAPK-related pathways

depending on ligand, receptor state, and cellular context.

That creates an important peptide principle:

LH AND hCG CAN ACT AT THE SAME RECEPTOR YET PRODUCE DIFFERENT SIGNALING PROFILES.

THE RECEPTOR MODEL

hCG → **LHCGR** → **Gs / cAMP** → **steroidogenic enzymes ↑** → **Potential:**

OVARIAN CELLS

PROGESTERONE / ANDROGEN SUPPORT

LEYDIG CELLS

TESTOSTERONE ↑

Again:

the same receptor produces different hormone outputs depending on:

THE CELL.

hCG IN EARLY PREGNANCY

The most important natural role of hCG is:

MAINTAINING LUTEAL FUNCTION BEFORE THE PLACENTA CAN FULLY TAKE OVER STEROIDOGENESIS.

Early pregnancy initially depends heavily on:

CORPUS-LUTEUM PROGESTERONE.

As placental steroid production increases:
the pregnancy becomes less dependent on:

THE CORPUS LUTEUM.


So hCG is especially important during:

THE TRANSITION PERIOD.

This is a beautiful example of:

TEMPORARY ENDOCRINE SUPPORT DURING ORGAN HANDOFF.

THE HANDOFF MODEL



Again:

hCG helps bridge:

OVARIAN SUPPORT

to:

PLACENTAL SUPPORT.

WHY PREGNANCY TESTS MEASURE hCG

hCG appears rapidly after implantation.

Because it is:

- produced by trophoblast tissue
- detectable in blood
- eventually detectable in urine

it becomes a useful marker of:

PREGNANCY.

But an hCG number is not simply:

PREGNANT / NOT PREGNANT.

Serial measurements can sometimes provide information about:

TRAJECTORY.

Again:

TREND CAN MATTER MORE THAN ONE NUMBER.

THE BIOMARKER MODEL

Single hCG measurement



confirms hormone presence

Serial hCG



provides information about:

CHANGE OVER TIME

But:

hCG alone does not define:

- location of pregnancy
- viability
- embryonic anatomy

Again:

BIOMARKER $\neq$ COMPLETE DIAGNOSIS.

hCG AND OVULATION

Because hCG activates:

THE LH RECEPTOR,

it can imitate the physiological:

LH SURGE.

That means pharmacological hCG can trigger:

FINAL OOCYTE MATURATION

and:

OVULATION.

This is one of its most established therapeutic uses.

The current U.S. label for chorionic gonadotropin includes induction of ovulation and pregnancy in appropriately selected anovulatory infertile women whose problem is secondary rather than primary ovarian failure.

THE OVULATION-TRIGGER MODEL



Again:

hCG is not:

CREATING THE FOLLICLE.

It is:

TRIGGERING THE FINAL STEP.

FINAL OOCYTE MATURATION

Before ovulation:

the oocyte must undergo:

FINAL MATURATION.

The LH surge normally initiates that process.

hCG can mimic the LH signal.

This is why hCG has been used for decades in:

- ovulation induction

IUI

IVF

The pharmacological logic is extremely coherent:

USE A LONGER-ACTING LH-RECEPTOR AGONIST TO RECREATE THE FINAL MATURATION SIGNAL.

hCG IN IVF

In IVF:

multiple follicles are intentionally stimulated.

Then clinicians need a precisely timed:

FINAL MATURATION TRIGGER.

hCG has historically been one of the standard triggers.

Current reviews still describe hCG as one of the most widely used agents for final oocyte maturation.

The tradeoff is:

PROLONGED LHCGR STIMULATION.

And that matters because of:

OHSS.

OVARIAN HYPERSTIMULATION SYNDROME - OHSS

OHSS is one of the major complications of controlled ovarian stimulation.

Potential manifestations include:

- enlarged ovaries
- ascites
- hemoconcentration
- renal dysfunction
- increased vascular permeability
- fluid shifts
- thrombosis
- respiratory compromise in severe cases

hCG plays an especially important role in:

TRIGGERING OR PROLONGING THE SYNDROME.

Reviews of OHSS prevention identify hCG exposure as a major driver in susceptible stimulated cycles.

THE OHSS MODEL



OHSS

This is why:

LONGER SIGNALING

can be both:

THE THERAPEUTIC ADVANTAGE

and:

THE SAFETY PROBLEM.

hCG VS GnRH AGONIST TRIGGER

This comparison directly connects to the previous GnRH guide.

hCG TRIGGER

Directly activates:

LHCGR

longer signal



strong luteal support

But:

OHSS RISK HIGHER IN SUSCEPTIBLE PATIENTS.

GnRH AGONIST TRIGGER

Stimulates pituitary



endogenous LH + FSH
surge



shorter physiological-type
signal



OHSS risk can be
dramatically reduced in
antagonist cycles.

So:

hCG = DIRECT LONG-ACTING RECEPTOR STIMULATION

while:

GnRH AGONIST = USE THE BODY'S OWN PITUITARY SURGE.

Again:

different levels of the axis.

hCG VS KISSPEPTIN TRIGGER

Now we can move one step further upstream.

hCG

acts directly on:

OVARIAN LHCGR

GnRH AGONIST

acts at:

PITUITARY GnRHR

- LH / FSH surge

KISSPEPTIN

acts at:

HYPOTHALAMIC KISS1R

GnRH



LH / FSH



ovary

So the hierarchy becomes:

KISSPEPTIN

GnRH



LH



LHCGR

And hCG enters:

AT THE BOTTOM OF THAT SIGNAL CASCADE.

That is a major systems-biology insight.

THE REPRODUCTIVE TRIGGER LADDER

MOST UPSTREAM

Kisspeptin



GnRH



LH



LHCGR



ovary

hCG

bypasses:

- hypothalamus
- pituitary

and directly activates:

LHCGR.

Again:

THE LOWER YOU ENTER THE PATHWAY, THE FEWER UPSTREAM SYSTEMS MUST BE FUNCTIONAL.

But:

you also lose some of the body's:

PHYSIOLOGICAL SELF-LIMITATION.

hCG IN MEN

hCG is extremely important in male reproductive endocrinology because:

LEYDIG CELLS EXPRESS LHCGR.

Normally:

LH

LHCGR



Leydig cells



TESTOSTERONE.

hCG can substitute pharmacologically for:

LH.

So:

hCG

LHCGR



Leydig-cell steroidogenesis



TESTOSTERONE ↑

This is why hCG has long been used in selected men with:

HYPOGONADOTROPIC HYPOGONADISM.

The FDA label includes selected cases of hypogonadotropic hypogonadism secondary to pituitary deficiency in males.

THE MALE MODEL

**Hypothalamus / pituitary
under-stimulates testis**



LH low



Leydig-cell stimulation low



Testosterone low

hCG



LHCGR



Leydig cells



TESTOSTERONE ↑

Again:

hCG bypasses:

THE PITUITARY.

hCG VS TESTOSTERONE REPLACEMENT

This distinction is fundamental.

TESTOSTERONE REPLACEMENT

Provides:

THE FINAL HORMONE DIRECTLY.

Systemic testosterone rises.

But:

negative feedback → GnRH ↓ → LH / FSH ↓ → intratesticular testosterone can fall. → spermatogenesis may fall.

hCG

Acts as an:

LH-RECEPTOR AGONIST.

Leydig cells make:

ENDOGENOUS TESTOSTERONE.

Intratesticular testosterone can be supported.

That may matter when:

FERTILITY IS A PRIORITY.

Again:

REPLACE THE OUTPUT

and:

STIMULATE THE ORGAN TO MAKE THE OUTPUT

are different strategies.

INTRATESTICULAR TESTOSTERONE

This concept is especially important.

Sperm production requires very high concentrations of:

TESTOSTERONE INSIDE THE TESTIS.

Serum testosterone does not perfectly represent:

INTRATESTICULAR TESTOSTERONE.

LH normally maintains this local testicular environment.

hCG can mimic:

LH SIGNALING

and therefore help preserve:

LEYDIG-CELL PRODUCTION.

This explains why hCG can be mechanistically useful in fertility-preserving approaches.

BUT hCG IS NOT FSH

This is equally important.

Spermatogenesis depends on both:

LH / hCG signaling



Leydig cells



intratesticular testosterone

and:

FSH

Sertoli-cell function



sperm development

So hCG alone may not fully restore:

SPERMATOGENESIS

in every patient with severe gonadotropin deficiency.

Again:

TESTOSTERONE PRODUCTION ≠ COMPLETE MALE FERTILITY.

THE MALE-FERTILITY MODEL

hCG



LHCGR



Leydig cell



Intratesticular testosterone ↑

But:

FSH

Sertoli cell



Spermatogenesis support

Therefore:

hCG MAY RESTORE ONE SIDE OF THE SYSTEM WITHOUT FULLY RESTORING THE OTHER.

That is why severe central hypogonadism may require:

MULTI-GONADOTROPIN THINKING.

hCG VS GnRH IN MEN

PULSATILE GnRH

Requires:

- intact pituitary

functional gonads



LH + FSH released naturally

hCG

Bypasses pituitary.



direct LHCGR activation

So if the pituitary cannot produce adequate LH:

hCG may still work.

But hCG does not recreate:

NORMAL FSH OUTPUT.

Again:

THE LEVEL OF THE LESION DETERMINES THE BEST ENTRY POINT.

hCG VS GONADORELIN

Gonadorelin is exogenous:

GnRH.

So:

Gonadorelin



pituitary



LH + FSH

while:

hCG

gonad



LHCGR

This creates another clean distinction:

GONADORELIN TESTS / STIMULATES THE PITUITARY.

hCG tests / stimulates:


THE GONADAL LH RECEPTOR SYSTEM.

hCG AND TESTICULAR FUNCTION AFTER TRT

One commonly discussed application is using hCG around:

EXOGENOUS TESTOSTERONE EXPOSURE.

The mechanistic concern is clear:



LEYDIG-CELL STIMULATION MAINTAINED

This is mechanistically logical.

But outcomes depend on:

- | | |
|----------------------|----------------------|
| • hCG regimen | • baseline fertility |
| • FSH status | • testicular reserve |
| • treatment duration | |

Again:

PRESERVING LEYDIG SIGNALING ≠ GUARANTEEING FERTILITY.

HYPOGONADOTROPIC HYPOGONADISM

This remains one of the strongest mechanistic male applications.

The pattern is:

LOW TESTOSTERONE

with:

LOW OR INAPPROPRIATELY NORMAL LH / FSH.

The gonad may still be capable.

The upstream signal is inadequate.

hCG can substitute for:

THE MISSING LH-LIKE SIGNAL.

The current chorionic-gonadotropin label explicitly includes selected male hypogonadotropic hypogonadism.

PRIMARY TESTICULAR FAILURE

Now consider the opposite.

Testosterone low.



LH high.



Pituitary is already asking:

THE TESTIS TO WORK.

If the testis cannot respond:

more LH-receptor stimulation through hCG may produce:

LIMITED BENEFIT.

Again:

HIGH ENDOGENOUS LH + LOW TESTOSTERONE

suggests:

DOWNSTREAM FAILURE.

This is not primarily:

AN hCG-DEFICIENT STATE.

THE FAILURE-LOCATION MODEL

CENTRAL FAILURE

LH low



testis under-stimulated



hCG may be mechanistically useful

PRIMARY TESTICULAR FAILURE

LH high



testis not responding



more receptor stimulation may not solve the problem

Again:

LOCALIZE THE FAILURE.

CRYPTORCHIDISM

hCG has also historically been used in:

PREPUBERTAL CRYPTORCHIDISM.

The rationale is:

hCG

LHCGR stimulation



androgen production ↑



potential contribution to testicular descent.

The U.S. label still includes prepubertal cryptorchidism not due to anatomical obstruction.

However, the effectiveness is limited.

A meta-analysis reported testicular descent rates around:

24% WITH hCG

and emphasized that hormonal treatment cannot be recommended universally because success is relatively low and long-term concerns remain.

Again:

BIOLOGICAL PLAUSIBILITY ≠ HIGH CLINICAL SUCCESS RATE.

THE CRYPTORCHIDISM LESSON

hCG can increase:

ANDROGEN SIGNALING.

That may assist descent when:

THE ANATOMICAL AND DEVELOPMENTAL SYSTEM REMAINS RESPONSIVE.

But if the problem is:

STRUCTURAL / MECHANICAL,

a stronger hormonal signal may not overcome:

ANATOMY.

Again:

SIGNAL $\neq$ STRUCTURAL CORRECTION.

hCG AND THE OVARY

In women:

LHCGR is expressed in:

- theca cells
- luteal cells
- selected granulosa cells after follicular maturation

This timing matters.

Early follicles depend heavily on:

FSH.

As follicles mature:

LHCGR expression increases in selected compartments.

So hCG becomes especially useful for:

FINAL MATURATION

rather than:

EARLY FOLLICULAR RECRUITMENT.

THE FOLLICULAR MODEL



Again:

THE SAME HORMONE IS NOT EQUALLY RELEVANT AT EVERY STAGE.

hCG AND LUTEAL SUPPORT

Because hCG provides prolonged:

LHCGR SIGNALING,

it can support:

CORPUS-LUTEUM PROGESTERONE PRODUCTION.

That is physiologically exactly what endogenous hCG does during:

EARLY PREGNANCY.

In assisted reproduction:

this creates potential use for:

LUTEAL SUPPORT.

But prolonged hCG activity also raises:

OHSS RISK

in susceptible patients.

Again:

the same property:

LONG HALF-LIFE

can be:

ADVANTAGE + DISADVANTAGE.

LOW-DOSE hCG

One strategy in fertility medicine has been:

LOWER-DOSING / TAILORED hCG.

The logic is:

achieve adequate:

LHCGR ACTIVATION

without unnecessary:

EXCESSIVE PROLONGED STIMULATION.

However, dose alone does not fully eliminate OHSS risk.

Older reviews specifically noted that reducing hCG trigger dose does not reliably eliminate OHSS.

Again:

RISK IS NOT JUST DOSE.

It also depends on:

- ovarian response
- estradiol environment
- luteal physiology
- follicle number
- receptor biology

URINARY VS RECOMBINANT hCG

Therapeutic hCG can come from:

URINARY-DERIVED PRODUCTS

or:

RECOMBINANT hCG.

A review comparing recombinant and urinary hCG found that recombinant hCG could produce similar final-oocyte-maturation outcomes to common urinary hCG regimens while offering improved product purity and fewer local injection-site reactions in the studies reviewed.

This is a useful manufacturing lesson.

SAME RECEPTOR TARGET

does not mean:

ALL PRODUCTS ARE IDENTICAL.

GLYCOSYLATION MATTERS

hCG is:

GLYCOSYLATED.

That means attached carbohydrate structures influence:

- half-life
- clearance
- receptor interaction
- signaling

Current LHCGR research emphasizes that glycosylation patterns can modify how LH and hCG interact with the receptor and which downstream pathways are activated.

That makes hCG a powerful example of:

POST-TRANSLATIONAL STRUCTURE MODIFYING PEPTIDE PHARMACOLOGY.

THE GLYCOSYLATION MODEL

- Protein backbone

carbohydrate modification



changes:

- stability
- clearance

receptor behavior



changes:

BIOLOGICAL EFFECT

Again:

SEQUENCE ALONE DOES NOT DEFINE THE MOLECULE.

hCG AND ENDOMETRIAL / IMPLANTATION BIOLOGY

Research has investigated hCG beyond:

CORPUS-LUTEUM RESCUE.

LHCGR expression and hCG effects have been explored in:

- endometrium
- uterine receptivity
- stromal cells
- implantation biology

A review of hCG reproductive actions described possible effects on endometrial receptivity and stromal function beyond the classic ovarian actions.

This is biologically interesting.

But the strongest established identity remains:

GONADAL LHCGR SIGNALING.

Again:

EXTRA-GONADAL RECEPTOR BIOLOGY ≠ AUTOMATIC THERAPEUTIC INDICATION.

hCG IN MALE BODY-COMPOSITION / WEIGHT-LOSS CULTURE

hCG has a long history of being promoted in some circles for:

WEIGHT LOSS.

This is not supported as an evidence-based weight-loss mechanism.

The central hCG biology is:

REPRODUCTIVE.

It should not be rebranded simply because:

THE HORMONE CAN ALTER SEX-STEROID SIGNALING.

Again:

HORMONAL EFFECT $\neq$ FAT-LOSS INDICATION.

hCG AND “PREGNANCY-LIKE” CLAIMS

Another common oversimplification is:

- “hCG puts the body into a pregnancy-like state.”

That is not a useful physiological description.

Pregnancy involves enormous changes in:

- progesterone
- placental hormones
- insulin resistance
- vascular function
- estrogen
- prolactin
- immune function

hCG is:

ONE IMPORTANT SIGNAL.

It does not reproduce:

THE ENTIRE PREGNANCY ENDOCRINE ENVIRONMENT.

THE CORE MECHANISM MAP

PHYSIOLOGICAL OR
EXOGENOUS hCG



LHCGR



Gs / cAMP + additional
signaling pathways



OVARY

FINAL OOCYTE MATURATION

LUTEINIZATION

PROGESTERONE SUPPORT

TESTIS

LEYDIG-CELL TESTOSTERONE PRODUCTION

EARLY PREGNANCY

CORPUS-LUTEUM RESCUE



Potential:

FERTILITY + REPRODUCTIVE FUNCTION + EARLY PREGNANCY SUPPORT

The core concept is:

hCG IS A LONG-ACTING LH-RECEPTOR SIGNAL WHOSE EFFECT DEPENDS ON WHETHER THE TARGET IS THE OVARY, CORPUS LUTEUM, OR TESTIS.

WHAT THIS MECHANISM MAY SUGGEST

Mechanistically and clinically, hCG deserves major relevance in:

- ovulation induction
- final oocyte maturation

IVF

- luteal support
- selected male hypogonadotropic hypogonadism
- male Leydig-cell stimulation
- reproductive diagnostic physiology
- early pregnancy physiology
- fertility preservation strategies
- selected cryptorchidism contexts

Its strongest established clinical domains are:

FERTILITY + GONADAL STIMULATION.

WHAT THIS MECHANISM DOES NOT PROVE

hCG biology does not prove that:

- every low-testosterone patient needs hCG
- higher hCG always produces better testosterone
- every infertile woman benefits from hCG
- low-dose hCG eliminates OHSS risk
- hCG reproduces the endocrine state of pregnancy
- all LHCGR activation is identical to natural LH signaling
- hCG restores fertility in primary testicular failure
- hCG alone guarantees spermatogenesis
- hCG is the safest trigger for every IVF patient
- hCG is a weight-loss hormone
- elevated hCG alone proves a normally developing intrauterine pregnancy

Again:

SAME RECEPTOR $\neq$ SAME PHYSIOLOGY.

THE EVIDENCE, POTENTIAL APPLICATIONS, AND LIMITATIONS

ENDOGENOUS PREGNANCY PHYSIOLOGY

VERY STRONG

hCG is an established trophoblast-derived hormone essential to:

EARLY LUTEAL SUPPORT.

Its role in:

- corpus-luteum rescue
- progesterone maintenance

is foundational reproductive physiology.

RECEPTOR BIOLOGY

VERY STRONG

hCG and LH act through:

LHCGR.

The receptor is a well-characterized GPCR capable of engaging multiple intracellular pathways.

FEMALE FERTILITY EVIDENCE

VERY STRONG

hCG has decades of established clinical use for:

- ovulation triggering
- final oocyte maturation
- fertility treatment

and remains an important trigger strategy.

MALE HYPOGONADISM EVIDENCE

ESTABLISHED IN SELECTED CENTRAL HYPOGONADISM

The U.S. label includes selected male hypogonadotropic hypogonadism.

The mechanistic fit is particularly strong when:

LH signaling is deficient but the testes remain responsive.

CRYPTORCHIDISM EVIDENCE

LIMITED

Meta-analysis suggests hormonal treatment can produce descent in some boys, but overall success rates are modest and the approach is not appropriate for all patients.

Again:

AN ESTABLISHED HORMONE DOES NOT HAVE EQUALLY STRONG EFFICACY IN EVERY APPLICATION.

- Research

EARLY PREGNANCY

This is hCG's defining endogenous domain.

Embryonic / placental tissue signals:

PREGNANCY EXISTS.

The maternal ovary responds.



Progesterone remains high enough to support:

THE EARLY ENDOMETRIUM.

This is:

EMBRYO-TO-MOTHER ENDOCRINE COMMUNICATION.

OVULATION INDUCTION

hCG is especially coherent when:

- follicles have matured
- ovaries can respond
- the missing step is final maturation / ovulation

The current U.S. product labeling specifically requires that the infertility be secondary and not due to primary ovarian failure.

That is a perfect example of:

DOWNSTREAM CAPACITY MATTERS.

IVF

hCG remains effective for:

FINAL OOCYTE MATURATION.

But patient response must be weighed against:

OHSS RISK.

A 2025 review again identifies hCG as a major trigger option while emphasizing GnRH agonist and emerging alternatives for patients requiring lower OHSS risk.

Again:

THE BEST TRIGGER IS PATIENT-SPECIFIC.

OHSS

This is perhaps hCG's most important reproductive safety issue.

The problem is not that hCG is:

"TOXIC."

The problem is:

PROLONGED LHCGR SIGNALING IN AN OVARY THAT HAS BEEN HEAVILY STIMULATED.

That is:

MECHANISM-BASED RISK.

MALE CENTRAL HYPOGONADISM

Here the pathway is extremely logical.

Pituitary LH inadequate.



testis under-stimulated.



hCG directly activates:

THE MISSING RECEPTOR SIGNAL.

If testosterone rises:

that demonstrates:

LEYDIG-CELL CAPACITY.

Again:

the treatment can also act as:

A FUNCTIONAL TEST OF THE TESTIS.

MALE INFERTILITY

The more complete question is not:

“DID TESTOSTERONE RISE?”

It is:

“DID SPERM PRODUCTION RECOVER?”

Because fertility requires:

- intratesticular testosterone

FSH

- Sertoli-cell function
- germ-cell capacity
- time

Again:

ENDOCRINE RESPONSE ≠ FERTILITY OUTCOME.

hCG DURING TRT

Mechanistically, hCG may help preserve:

LEYDIG-CELL SIGNALING

when exogenous testosterone suppresses:

LH.

But the actual treatment goal must be explicit:

fertility?

testicular volume?

intratesticular testosterone?

symptom management?

Again:

DO NOT USE ONE LAB AS A SUBSTITUTE FOR THE CLINICAL GOAL.

PRIMARY TESTICULAR FAILURE

Here hCG may be far less effective because:

the problem is not:

MISSING LH-LIKE SIGNAL.

The problem is:

THE TESTIS CANNOT RESPOND ADEQUATELY.

Again:

more signaling cannot restore:

LOST TARGET-TISSUE CAPACITY.

PRIMARY OVARIAN FAILURE

The same principle applies.

If:

- FSH / LH already high

and:

- ovarian reserve is severely depleted,

hCG does not recreate:

LOST FOLLICLES.

This is exactly why the current label excludes primary ovarian failure from ovulation-induction use.

hCG AS A FUNCTIONAL CHALLENGE

hCG can also be conceptually useful as:

A PHYSIOLOGICAL CHALLENGE.

For example:

hCG given



Leydig cells stimulated



testosterone measured



provides information about:

TESTICULAR RESPONSIVENESS

Again:

a peptide / hormone can provide:

INFORMATION ABOUT SYSTEM CAPACITY.

WHAT WE KNOW

hCG is a placental glycoprotein hormone composed of alpha and beta subunits.

It is produced predominantly by trophoblast tissue after implantation.

Its defining endogenous role is maintenance of the corpus luteum during early pregnancy.

hCG supports corpus-luteum progesterone production until placental steroidogenesis becomes sufficient.

hCG and LH act through the same receptor: LHCGR.

LHCGR is a GPCR capable of signaling through cAMP-dependent and additional pathways.

hCG has a substantially longer biological duration than endogenous LH.

That prolonged signaling is one of the reasons it is useful pharmacologically.

It is also one of the reasons it can contribute to OHSS in susceptible stimulated ovaries.

hCG can trigger final oocyte maturation and ovulation.

It remains one of the most widely used trigger agents in assisted reproduction.

The current U.S. chorionic-gonadotropin label includes induction of ovulation and pregnancy in appropriately selected anovulatory infertile women whose problem is not primary ovarian failure.

In men, hCG acts primarily as an LH-receptor agonist on Leydig cells.

This can increase endogenous testicular testosterone production.

The current U.S. label also includes selected cases of male hypogonadotropic hypogonadism.

hCG does not reproduce the full action of FSH.

Therefore, restoration of testosterone does not automatically mean restoration of spermatogenesis.

hCG and testosterone replacement should not be treated as mechanistically identical.

Exogenous testosterone supplies the downstream hormone and suppresses gonadotropin signaling through negative feedback.

hCG stimulates the testis through LHCGR and can preserve endogenous Leydig-cell activity.

hCG has historically also been used in cryptorchidism, although success rates are limited.

A meta-analysis reported approximately 24% testicular descent with hCG and emphasized that hormonal treatment is not appropriate for every patient.

hCG-based ovulation triggering carries a clinically important OHSS risk in high-response fertility cycles.

GnRH-agonist triggering can reduce that risk substantially in appropriate antagonist cycles because it produces a shorter endogenous LH / FSH surge rather than prolonged direct LHCGR stimulation.

This makes hCG an excellent example of why signal duration matters as much as receptor identity.

WHAT WE THINK MAY BE HAPPENING

hCG may be best understood as:

THE BODY'S LONG-ACTING LH-RECEPTOR SIGNAL.

In pregnancy:

the embryo implants. → Placental tissue begins communicating. → hCG enters maternal circulation. → The ovary receives:

“PREGNANCY HAS OCCURRED.” → The corpus luteum remains active. → Progesterone stays high. → The pregnancy continues through a vulnerable endocrine transition.

In fertility treatment:

we use the same receptor system for a different reason.

hCG tells the mature follicle:

“THE LH SIGNAL HAS ARRIVED - COMPLETE OOCYTE MATURATION.”

And in men:

hCG tells the Leydig cell:

“THE LH SIGNAL HAS ARRIVED - PRODUCE TESTOSTERONE.”

So:

same molecule.

Same receptor.

Three different contexts:

EARLY PREGNANCY

OVULATION

TESTICULAR STEROIDOGENESIS

That is systems physiology.

WHAT REMAINS CONTEXT-DEPENDENT

Important questions include:

How differently do LH and hCG signal through LHCGR?

Which downstream pathways are ligand-biased?

How much do glycosylation patterns alter receptor signaling?

How should urinary and recombinant hCG products be compared?

What is the optimal hCG exposure for final oocyte maturation?

Can OHSS risk be reduced without compromising oocyte maturity?

Which patients should preferentially receive GnRH-agonist or kisspeptin triggers instead?

What is the optimal role of low-dose hCG in luteal support?

How should dual-trigger protocols be individualized?

Which male hypogonadism phenotypes respond best to hCG?

What degree of baseline testicular reserve predicts response?

How much FSH support is needed for spermatogenesis in severe central hypogonadism?

What is the best way to preserve fertility in men using exogenous testosterone?

How much hCG is actually required to preserve intratesticular testosterone?
Does prolonged hCG use alter Leydig-cell responsiveness?
How should estradiol changes be interpreted in men receiving hCG?
Which hCG isoforms have distinct biological roles in pregnancy?
How does hyperglycosylated hCG differ from conventional circulating hCG?
What extra-gonadal LHCGR actions are physiologically important?
How important is hCG signaling to endometrial receptivity?
Can hCG-based challenge testing better phenotype Leydig-cell function?
Which cryptorchidism phenotypes are genuinely hormone responsive?
How should long-term reproductive outcomes after hormonal cryptorchidism treatment be interpreted?
Can receptor-biased LHCGR agonists reproduce useful hCG effects with less OHSS risk?

Again:

these are the questions needed to move from:

LH-LIKE HORMONE

to:

PRECISION GONADAL RECEPTOR PHARMACOLOGY.

THE PRAXIS LENS

DO NOT BEGIN WITH hCG

Begin with:

WHICH LH-RECEPTOR-DEPENDENT FUNCTION ARE WE ACTUALLY TRYING TO CHANGE?

Then:

PHYSIOLOGY

PATTERN → **MECHANISM** → **EVIDENCE** → **RISK** → **MONITORING** → **DECISION**

PHYSIOLOGY

Normal LHCGR-dependent physiology requires:

- appropriate LH or hCG signal
- responsive ovarian or testicular tissue
- appropriate FSH context where fertility is the goal
- functional receptor
- adequate gonadal reserve
- correct timing

hCG is especially relevant to:

THE GONADAL LH-RECEPTOR STEP.

PATTERN

What is actually present?

anovulation?

IVF trigger requirement?

hypogonadotropic hypogonadism?

low testosterone?

infertility?

impaired Leydig-cell stimulation?

early pregnancy?

primary gonadal failure?

Again:

“LOW TESTOSTERONE” IS NOT AN hCG DIAGNOSIS.

MECHANISM

Does hCG biology match:

THE BOTTLENECK?

If LH is low:

and:

- the testes are responsive,

hCG becomes:

HIGHLY MECHANISTICALLY COHERENT.

If LH is already high and testosterone remains low:

the testis may be:

THE FAILED NODE.

If infertility is caused by:

PRIMARY OVARIAN FAILURE,

an hCG trigger cannot restore:

ABSENT FOLLICULAR CAPACITY.

Again:

RECEPTOR STIMULATION REQUIRES TARGET-TISSUE CAPACITY.

EVIDENCE

Ask:

WHAT APPLICATION ARE WE DISCUSSING?

Early pregnancy physiology?

VERY STRONG.

Ovulation / IVF triggering?

VERY STRONG ESTABLISHED CLINICAL EVIDENCE.

Male central hypogonadism?

ESTABLISHED IN SELECTED PATIENTS.

Fertility preservation during TRT?

MECHANISTICALLY STRONG BUT REGIMEN-DEPENDENT.

Weight loss?

NOT A SUPPORTED REPRODUCTIVE INDICATION.

Again:

SAME MOLECULE. DIFFERENT EVIDENCE CLASS.

RISK

Risk depends strongly on:

SEX + REPRODUCTIVE CONTEXT + DOSE + TARGET.

FEMALE FERTILITY CONTEXT

Potential:

OHSS	
<ul style="list-style-type: none">• ovarian enlargement• thrombotic complications in severe OHSS• multiple gestation in fertility protocols	<ul style="list-style-type: none">• abdominal symptoms• mistimed ovulation

MALE CONTEXT

Potential:

<ul style="list-style-type: none">• estradiol increase• gynecomastia• androgenic symptoms	<ul style="list-style-type: none">• fluid retention• acne• excessive testosterone response
---	--

The current label also includes product-specific adverse-effect and contraindication considerations.

Again:

THE SAME RECEPTOR THAT PRODUCES THE BENEFIT CAN PRODUCE THE TRADEOFF.

MONITORING

Monitoring should follow:

THE hCG HYPOTHESIS.

MALE HYPOGONADISM / FERTILITY

<ul style="list-style-type: none">• testosterone• LH / FSH context• semen analysis• symptoms	<ul style="list-style-type: none">• estradiol• testicular volume• fertility outcomes
---	--

FEMALE OVULATION / IVF

<ul style="list-style-type: none">• follicular development• oocyte maturation• ovarian response• pregnancy outcome	<ul style="list-style-type: none">• estradiol• ovulation timing• OHSS risk
---	--

EARLY PREGNANCY

where clinically appropriate:

- serial hCG
- ultrasound findings
- progesterone
- clinical symptoms

Again:

monitor:

THE FUNCTION THE LHCGR SIGNAL IS SUPPOSED TO PRODUCE.

THE PRAXIS 5

MECHANISM

hCG's dominant pathway is:

hCG → LHCGR → cAMP / steroidogenic signaling.

Its major biological outputs include:

CORPUS-LUTEUM SUPPORT + OOCYTE MATURATION + LEYDIG-CELL TESTOSTERONE PRODUCTION.

EVIDENCE

Pregnancy physiology:

VERY STRONG.

Receptor biology:

VERY STRONG.

Ovulation / IVF:

VERY STRONG.

Male central hypogonadism:

ESTABLISHED.

Cryptorchidism:

LIMITED / SELECTED.

RISK

The major conceptual mistake is:

ASSUMING hCG IS SIMPLY "LH WITH A DIFFERENT NAME."

It uses the same receptor.

But:

HALF-LIFE + GLYCOSYLATION + SIGNALING PROFILE + EXPOSURE ARE DIFFERENT.

That difference is clinically important.

MONITORING

Monitor:

THE GONADAL RESPONSE.

If male:

did Leydig-cell testosterone production improve?

If fertility:

did sperm production improve?

If female IVF:

did oocyte maturation occur without excessive ovarian response?

Again:

THE RECEPTOR RESPONSE SHOULD TRANSLATE INTO THE ACTUAL GOAL.

PATIENT CONTEXT

A man with:

LOW LH + LOW TESTOSTERONE

is not identical to:

someone with:

HIGH LH + LOW TESTOSTERONE.

A woman with:

MATURE STIMULATED FOLLICLES

is not identical to:

someone with:

PRIMARY OVARIAN INSUFFICIENCY.

A high-risk IVF patient is not identical to:

a low-risk ovulation-induction patient.

Same hormone.

Different:

GONADAL CONTEXT.

SEVEN QUESTIONS TO ASK BEFORE hCG

1. WHAT LHCGR-DEPENDENT FUNCTION ARE WE TRYING TO CHANGE?

testosterone?

ovulation?

oocyte maturation?

luteal support?

fertility?

2. WHERE IS THE REPRODUCTIVE FAILURE?

hypothalamus?

pituitary?

ovary?

testis?

3. CAN THE TARGET GONAD ACTUALLY RESPOND?

This is crucial.

High endogenous LH with low gonadal output suggests:

TARGET-TISSUE FAILURE.

4. DO WE NEED LH-LIKE SIGNALING - OR A MORE UPSTREAM STRATEGY?

Would:

- Kisspeptin

GnRH

hCG

best match the failed level?

5. WHAT TYPE OF EVIDENCE SUPPORTS THIS APPLICATION?

pregnancy physiology?

IVF?

central hypogonadism?

fertility preservation?

exploratory use?

6. WHAT WILL WE MONITOR?

testosterone?

estradiol?

semen analysis?

follicular response?

oocyte maturity?

OHSS?**7. WHAT WOULD DEFINE SUCCESS?**

Not:

“hCG RAISED A HORMONE.”

But:

THE GONAD RESPONDED IN THE INTENDED WAY - TESTOSTERONE PRODUCTION, SPERMATOGENESIS, OOCYTE MATURATION, OVULATION, OR LUTEAL SUPPORT IMPROVED - WITHOUT CREATING AN EXCESSIVE REPRODUCTIVE OR METABOLIC TRADEOFF.

KEY TAKEAWAYS

hCG is a trophoblast-derived glycoprotein hormone central to early pregnancy.

Its defining natural function is rescue and maintenance of the corpus luteum after implantation.

This allows progesterone production to continue until placental steroidogenesis becomes sufficient.

hCG and LH act through the same receptor: LHCGR.

That receptor is a GPCR with classical Gs / cAMP signaling and additional G-protein and β -arrestin pathways.

hCG should therefore not be understood merely as “the pregnancy-test hormone.”

It is a functional LH-receptor agonist with a prolonged biological signal.

That longer duration distinguishes it from endogenous LH.

This difference is a major reason hCG is useful therapeutically.

It is also a major reason it can increase OHSS risk in strongly stimulated ovaries.

hCG is a well-established trigger for final oocyte maturation and ovulation.

It remains widely used in fertility medicine.

The current U.S. label includes ovulation induction in appropriately selected infertile women when the problem is secondary and not primary ovarian failure.

This illustrates an essential principle: the ovary must still possess the capacity to respond.

hCG also has an established role in selected men with hypogonadotropic hypogonadism.

In men, hCG mimics LH at Leydig-cell LHCGR and increases endogenous testicular testosterone production.

That is fundamentally different from simply administering testosterone.

Exogenous testosterone supplies the final hormone and can suppress LH and FSH through negative feedback.

hCG stimulates the testis to produce testosterone through the normal LH receptor.

This can be particularly important when fertility or intratesticular testosterone matters.

But hCG is not FSH.

Restoring Leydig-cell testosterone production does not automatically restore normal spermatogenesis.

That is why male fertility requires more than one endocrine node.

The location of failure matters enormously.

Low testosterone with low or inappropriately normal LH suggests an upstream problem in which hCG may be mechanistically useful.

Low testosterone with high LH suggests the testis is already receiving a strong signal and may not be able to respond appropriately.

More hCG does not automatically correct that downstream failure.

In fertility medicine, hCG directly activates the ovarian LH receptor.

GnRH agonist triggers act one level upstream through the pituitary.

Kisspeptin acts another level upstream through GnRH neurons.

This gives us a complete trigger hierarchy:

KISSEPTIN → GnRH → LH → LHCGR.

hCG enters directly at the final receptor step.

The farther downstream the therapy acts, the fewer upstream systems it depends on.

But it also bypasses some of the physiological self-limiting controls of the native axis.

That becomes especially relevant in OHSS.

GnRH-agonist triggering can substantially reduce OHSS risk in appropriate antagonist cycles by producing a shorter endogenous LH / FSH surge rather than prolonged hCG exposure.

hCG has also historically been used for cryptorchidism.

However, the clinical success rate is modest, and hormonal treatment is not appropriate for every patient.

This again shows that mechanistic plausibility and clinical effectiveness are not identical.

hCG is also structurally more complex than a simple peptide sequence because glycosylation meaningfully modifies its pharmacology.

That makes hCG an important example of post-translational structure altering receptor behavior and half-life.

The best question is not “does hCG raise testosterone or trigger ovulation?”

The better question is “where is the reproductive axis failing, is the target gonad capable of responding, do we need direct LHCGR stimulation or a more physiological upstream signal, and can the hCG response produce the desired reproductive function without excessive receptor exposure or downstream risk?”

THE BOTTOM LINE

hCG may be one of the best examples in the reproductive system of:

THE SAME RECEPTOR BEING USED FOR DIFFERENT BIOLOGICAL PURPOSES.

In early pregnancy:

the trophoblast sends:

hCG.

The corpus luteum receives:

STAY ALIVE.

Progesterone continues.



The early pregnancy remains supported.

In fertility medicine:

the mature follicle receives:

hCG.

The message becomes:

THE LH SURGE HAS ARRIVED - COMPLETE MATURATION.

The oocyte matures.



Ovulation becomes possible.

And in men:

the Leydig cell receives:

hCG.

The message becomes:

THE LH SIGNAL HAS ARRIVED - PRODUCE TESTOSTERONE.

Same receptor.

Different tissue.

Different:

PHYSIOLOGICAL OUTCOME.

But hCG also teaches a deeper pharmacology lesson.

The body normally uses:

LH

as a relatively brief signal.

hCG produces:

A LONGER SIGNAL.

That prolonged stimulation can be extremely useful.

It can preserve:

THE CORPUS LUTEUM.

It can reliably trigger:

OOCYTE MATURATION.

It can stimulate:

LEYDIG-CELL TESTOSTERONE PRODUCTION.

But in a heavily stimulated ovary:

the same prolonged signal can contribute to:

OHSS.

That means:

THE PROPERTY THAT MAKES A DRUG EFFECTIVE CAN ALSO CREATE ITS RISK.

This is exactly why peptide medicine cannot stop at:

“WHAT RECEPTOR DOES IT HIT?”

We also have to ask:

for how long?

in which tissue?

at what stage?

with what downstream reserve?

in what patient?

And hCG gives us another powerful systems distinction.

You can stimulate reproduction at several levels:

KISSPEPTIN

GnRH



LH



LHCGR

The clinician can choose:

WHERE TO ENTER THE SYSTEM.

That decision should depend on:

WHERE THE SYSTEM FAILED.

So the Praxis question becomes:

“WHAT reproductive function are we trying to restore or control, where along the hypothalamic-pituitary-gonadal axis is the actual failure, is the ovary or testis capable of responding to LHCGR stimulation, and does direct hCG signaling provide the right duration and magnitude of receptor activation for the goal without creating an unnecessary reproductive or endocrine tradeoff?”

That is the difference between:

CALLING hCG THE PREGNANCY HORMONE

and:

UNDERSTANDING LONG-ACTING LH-RECEPTOR SIGNALING.

FINAL RECALL

TARGET Identify the LHCGR-dependent function	LOCALIZE Confirm the gonad can still respond	VERIFY Measure pregnancy, maturation, testosterone, or fertility - not signal alone
--	--	---

STOP MEMORIZING PEPTIDES. START UNDERSTANDING THE SYSTEM.

Praxis Peptide Institute provides educational information and is not a substitute for individualized medical diagnosis or treatment. hCG is a placental glycoprotein hormone with established roles in corpus-luteum support, early-pregnancy physiology, final oocyte maturation, ovulation triggering, and LH-receptor-mediated testosterone production. Its clinical relevance depends on whether the target gonad can respond, whether the underlying problem is hypothalamic, pituitary, ovarian, or testicular, whether the objective is fertility, steroidogenesis, ovulation, or luteal support, and whether prolonged LHCGR activation creates unacceptable risk such as excessive ovarian stimulation. hCG should be interpreted as a long-acting LH-receptor signal rather than as a generic testosterone, fertility, pregnancy, or weight-loss hormone.